Search

Your search keyword '"Genge, Angela"' showing total 15 results
Start Over Author "Genge, Angela" Journal amyotrophic lateral sclerosis and frontotemporal degeneration
15 results on '"Genge, Angela"'

3. COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success

Author

Shefner, Jeremy M., primary, Al-Chalabi, Ammar, additional, Andrews, Jinsy A., additional, Chio, Adriano, additional, De Carvalho, Mamede, additional, Cockroft, Bettina M., additional, Corcia, Philippe, additional, Couratier, Philippe, additional, Cudkowicz, Merit E., additional, Genge, Angela, additional, Hardiman, Orla, additional, Heiman-Patterson, Terry, additional, Henderson, Robert D., additional, Ingre, Caroline, additional, Jackson, Carlayne E., additional, Johnston, Wendy, additional, Lechtzin, Noah, additional, Ludolph, Albert, additional, Maragakis, Nicholas J., additional, Miller, Timothy M., additional, Mora Pardina, Jesus S., additional, Petri, Susanne, additional, Simmons, Zachary, additional, Van Den Berg, Leonard H., additional, Zinman, Lorne, additional, Kupfer, Stuart, additional, Malik, Fady I., additional, Meng, Lisa, additional, Simkins, Tyrell J., additional, Wei, Jenny, additional, Wolff, Andrew A., additional, and Rudnicki, Stacy A., additional

Published
2023
Full Text
View/download PDF

5. MiToS and King’s staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial

Author

Gebrehiwet, Paulos, primary, Meng, Lisa, additional, Rudnicki, Stacy A., additional, Sarocco, Phil, additional, Wei, Jenny, additional, Wolff, Andrew A., additional, Chiò, Adriano, additional, Andrews, Jinsy A., additional, Genge, Angela, additional, Jackson, Carlayne E., additional, Lechtzin, Noah, additional, Miller, Timothy M., additional, and Shefner, Jeremy M., additional

Published
2022
Full Text
View/download PDF

6. CAPTURE ALS: the comprehensive analysis platform to understand, remedy and eliminate ALS

Author

Picher-Martel, Vincent, primary, Magnussen, Claire, additional, Blais, Mathieu, additional, Bubela, Tania, additional, Das, Samir, additional, Dionne, Annie, additional, Evans, Alan C., additional, Genge, Angela, additional, Greiner, Russell, additional, Iturria-Medina, Yasser, additional, Johnston, Wendy, additional, Jones, Kelvin, additional, Kaneb, Hannah, additional, Karamchandani, Jason, additional, Moradipoor, Sara, additional, Robertson, Janice, additional, Rogaeva, Ekaterina, additional, Taylor, David M., additional, Vande Velde, Christine, additional, Yunusova, Yana, additional, Zinman, Lorne, additional, Kalra, Sanjay, additional, and Dupré, Nicolas, additional

Published
2022
Full Text
View/download PDF

7. Genetic testing for amyotrophic lateral sclerosis in Canada – an assessment of current practices

Author

Salmon, Kristiana, primary, Anoja, Nancy, additional, Breiner, Ari, additional, Chum, Marvin, additional, Dionne, Annie, additional, Dupré, Nicolas, additional, Fiander, Amanda, additional, Fok, Daniel, additional, Ghavanini, Amer, additional, Gosselin, Sylvie, additional, Izenberg, Aaron, additional, Johnston, Wendy, additional, Kalra, Sanjay, additional, Matte, Geneviève, additional, Melanson, Michel, additional, O’Connell, Colleen, additional, Ritsma, Benjamin, additional, Schellenberg, Kerri, additional, Shoesmith, Christen, additional, Tremblay, Sandra, additional, Williams, Heather, additional, and Genge, Angela, additional

Published
2021
Full Text
View/download PDF

8. A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis

Author

Shefner, Jeremy M, Cudkowicz, Merit E, Hardiman, Orla, Cockroft, Bettina M, Lee, Jacqueline H, Malik, Fady, Meng, Lisa, Rudnicki, Stacy A, Wolff, Andrew A, Andrews, Jinsy A, Van Damme, Philip, Korngut, Lawrence, Johnston, Wendy, O'Connell, Colleen, Grant, Ian, Turnbull, John, Shoesmith, Christen, Zinman, Lorne, Botez, Stephan, Genge, Angela, Dionne, Annie, Couratier, Philippe, Attarian, Shahram, Pouget, Jean, Camu, William, Desnuelle, Claude, Salachas, Francois, Corcia, Philippe, Meyer, Thomas, Petri, Susanne, Ludolph, Albert, Calvo, Andrea, Lunetta, Christian, Silani, Vincenzo, van den Berg, Leonard, de Carvalho, Mamede, Mora Pardina, Jesus, Young, Carolyn, Al-Chalabi, Ammar, Radunovic, Aleksander, Hanemann, Clemens, Ladha, Shafeeq, Goyal, Namita, Ravits, John, Lewis, Richard, Joyce, Nanette, Oskarsson, Bjorn, Katz, Jonathan S, So, Yuen, Quan, Dianna, Felice, Kevin, Bayat, Elham, Boylan, Kevin, Benatar, Michael G, Tuan, Vu, Glass, Jonathan, Sufit, Robert, Bodkin, Cynthia, Swenson, Andrea, Statland, Jeffrey, Maragakis, Nicholas, Berry, James, Brown, Robert, Salameh, Johnny, Goutman, Stephen, Newman, Daniel S, Guliani, Gaurav, Maiser, Samuel, Pestronk, Alan, Hayat, Ghazala, Pattee, Gary, Cohen, Jeffrey, Brooks, Benjamin, Bedlack, Richard, Caress, James, Mitsumoto, Hiroshi, Lange, Dale, Bradshaw, Deborah, Kolb, Stephen J, Karam, Chafic, Khoury, Julie, Goslin, Kimberly, Simmons, Zachary, Mc Cluskey, Leo, Heiman-Patterson, Terry, Donofrio, Peter, Heitzman, Daragh, Harati, Yadollah, Jackson, Carlayne, Phillips, Lawrence, Weiss, Michael, Nance, Christopher, Sultan, Shumaila, Barkhaus, Paul, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), and Trinity College Dublin

Subjects
amyotrophic lateral sclerosis, medicine.medical_specialty, Tirasemtiv, tirasemtiv, [SDV]Life Sciences [q-bio], [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Clinical Neurology, Placebo, law.invention, ACTIVATION, DOUBLE-BLIND, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, medicine, In patient, Amyotrophic lateral sclerosis, Science & Technology, PLACEBO, biology, business.industry, Skeletal muscle, EFFICACY, medicine.disease, Troponin, Clinical trial, medicine.anatomical_structure, Neurology, SAFETY, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, biology.protein, Cardiology, Neurosciences & Neurology, Randomized clinical trial, Neurology (clinical), business, Life Sciences & Biomedicine, 030217 neurology & neurosurgery
Abstract

OBJECTIVE: To assess the efficacy of tirasemtiv, a fast skeletal muscle troponin activator, vs. placebo in patients with amyotrophic lateral sclerosis. Methods: VITALITY-ALS (NCT02496767) was a multinational, double-blind, randomized, placebo-controlled clinical trial. Participants tolerating 2 weeks of open-label tirasemtiv (125 mg twice daily) were randomized 3:2:2:2 to placebo or one of three target tirasemtiv dose levels, using an escalating dosage protocol lasting 28 days. The primary outcome measure was changed in slow vital capacity (SVC) at 24 weeks. Secondary endpoints included a change in muscle strength and time to respiratory milestones of disease progression. RESULTS: Of 744 participants, 565 tolerated open-label tirasemtiv and received randomized treatment. By 24 weeks, 23 (12.2%) placebo-treated participants discontinued study treatment vs. 129 (34.2%) randomized to tirasemtiv. SVC declined by 14.4% (95% CI: −16.8, −11.9) in the placebo group and 13.4% (95% CI: −15.3, −11.6) in the tirasemtiv group (p = 0.56). Secondary endpoints did not show significant differences. However, participants who tolerated tirasemtiv at their randomized dose showed a numeric trend toward a dose-related slowing of decline in SVC (p = 0.11). Dizziness, fatigue, nausea, weight loss, and insomnia occurred more frequently on tirasemtiv. Serious adverse events were similar across groups. CONCLUSIONS: Tirasemtiv did not alter the decline of SVC or significantly impact secondary outcome measures. Poor tolerability of tirasemtiv may have contributed to this result. However, participants tolerating their intended dose exhibited a trend toward treatment benefit on SVC, suggesting the underlying mechanism of action may still hold promise, as is being tested with a different fast skeletal muscle troponin activator (NCT03160898). ispartof: AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION vol:20 issue:7-8 pages:584-594 ispartof: location:England status: published

Published
2019

9. A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS

Author

Shefner, Jeremy M., primary, Andrews, Jinsy A., additional, Genge, Angela, additional, Jackson, Carlayne, additional, Lechtzin, Noah, additional, Miller, Timothy M., additional, Cockroft, Bettina M., additional, Meng, Lisa, additional, Wei, Jenny, additional, Wolff, Andrew A., additional, Malik, Fady I., additional, Bodkin, Cynthia, additional, Brooks, Benjamin R., additional, Caress, James, additional, Dionne, Annie, additional, Fee, Dominic, additional, Goutman, Stephen A., additional, Goyal, Namita A., additional, Hardiman, Orla, additional, Hayat, Ghazala, additional, Heiman-Patterson, Terry, additional, Heitzman, Daragh, additional, Henderson, Robert D., additional, Johnston, Wendy, additional, Karam, Chafic, additional, Kiernan, Matthew C., additional, Kolb, Stephen J., additional, Korngut, Lawrence, additional, Ladha, Shafeeq, additional, Matte, Genevieve, additional, Mora, Jesus S., additional, Needham, Merrilee, additional, Oskarsson, Bjorn, additional, Pattee, Gary L., additional, Pioro, Erik P., additional, Pulley, Michael, additional, Quan, Dianna, additional, Rezania, Kourosh, additional, Schellenberg, Kerri L., additional, Schultz, David, additional, Shoesmith, Christen, additional, Simmons, Zachary, additional, Statland, Jeffrey, additional, Sultan, Shumaila, additional, Swenson, Andrea, additional, Berg, Leonard H. Van Den, additional, Vu, Tuan, additional, Vucic, Steve, additional, Weiss, Michael, additional, Whyte-Rayson, Ashley, additional, Wymer, James, additional, Zinman, Lorne, additional, and Rudnicki, Stacy A., additional

Published
2020
Full Text
View/download PDF

10. Reliability and validity of speech & pause measures during passage reading in ALS

Author

Barnett, Carolina, primary, Green, Jordan R., additional, Marzouqah, Reeman, additional, Stipancic, Kaila L., additional, Berry, James D., additional, Korngut, Lawrence, additional, Genge, Angela, additional, Shoesmith, Christen, additional, Briemberg, Hannah, additional, Abrahao, Agessandro, additional, Kalra, Sanjay, additional, Zinman, Lorne, additional, and Yunusova, Yana, additional

Published
2019
Full Text
View/download PDF

14. Understanding the use of NIV in ALS: results of an international ALS specialist survey

Author

Heiman-Patterson, Terry D., primary, Cudkowicz, Merit E., additional, De Carvalho, Mamede, additional, Genge, Angela, additional, Hardiman, Orla, additional, Jackson, Carlayne E., additional, Lechtzin, Noah, additional, Mitsumoto, Hiroshi, additional, Silani, Vincenzo, additional, Andrews, Jinsy A., additional, Chen, Dafeng, additional, Kulke, Sarah, additional, Rudnicki, Stacy A., additional, and van den Berg, Leonard H., additional

Published
2018
Full Text
View/download PDF

15. Respiratory measures in amyotrophic lateral sclerosis

Author

Lechtzin, Noah, primary, Cudkowicz, Merit E., additional, de Carvalho, Mamede, additional, Genge, Angela, additional, Hardiman, Orla, additional, Mitsumoto, Hiroshi, additional, Mora, Jesus S., additional, Shefner, Jeremy, additional, Van den Berg, Leonard H., additional, and Andrews, Jinsy A., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results